# 510(k) Summary (Prepared on September 26th, 2006)

This 510(k) Summary is submitted in accordance with 21 CFR 807.92.

<table>
<thead>
<tr>
<th>Trade Names:</th>
<th>Aquadex FlexFlow™ System (trademark pending)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer:</td>
<td>CHF Solutions, Inc., Suite 170 - 7601 Northland Drive, Brooklyn Park, MN 55428</td>
</tr>
<tr>
<td>Official Contact:</td>
<td>Chris Scavotto, QA Director Telephone: 763-463-4621, Fax: 763-463-4606</td>
</tr>
<tr>
<td>Device Generic Name:</td>
<td>Ultrafiltration (Aquapheresis) System</td>
</tr>
<tr>
<td>Classification:</td>
<td>High permeability dialysis systems - classified as Class II</td>
</tr>
<tr>
<td>Predicate Devices:</td>
<td>Aquadex FlexFlow System (K060008)</td>
</tr>
<tr>
<td>Device Description:</td>
<td>The Aquadex FlexFlow System removes excess fluid from the patient in fluid overload by ultrafiltration of blood across a hollow-fiber hemofilter at the clinician selected rate. The system is comprised on a console mounted on a cart, proprietary software and accessories (venous access catheters, extensions and a blood pump circuit). Patient access is obtained via either peripheral or central venous veins.</td>
</tr>
</tbody>
</table>
| Indication for Use: | The Aquadex FlexFlow™ System is indicated for:  
- Temporary (up to 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and  
- Extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a health care provider, under physician prescription, both of whom having received training in extracorporeal therapies. |
| Safety & Performance: | Regression testing was performed to verify and validate the software change and to generate data in support of the labeling change which incorporates a catheter compatibility chart using the principles of ISO 14971:2000 “Medical devices – Application of risk management to medical devices. Data generated demonstrated the Aquadex FlexFlow System continues to be safe and effective. |
| Conclusion: | Based on the similar intended use, patient population, technology characteristics, and performance as assessed |
Mr. Chris Scavotto  
Director of Quality Assurance  
CHF Solutions, Inc.  
7601 Northland Dr., Ste. 170  
BROOKLYN PARK MN  55428

Re: K062922  
Trade/Device Name: Aquadex™ FlexFlow™ System  
Regulation Number: 21 CFR §876.5860  
Regulation Name: High permeability hemodialysis system  
Regulatory Class: II  
Product Code: KDI  
Dated: October 30, 2006  
Received: November 13, 2006

Dear Mr. Scavotto:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

- 21 CFR 876.xxx (Gastroenterology/Renal/Urology) 240-276-0115
- 21 CFR 884.xxx (Obstetrics/Gynecology) 240-276-0115
- 21 CFR 894.xxx (Radiology) 240-276-0120
- Other 240-276-0100

Also, please note the regulation entitled, “Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Nancy C. Brogdon
Director, Division of Reproductive, Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
INDICATIONS FOR USE STATEMENT

510(k) Number (if known): K06 2A 22.

Device Name: Aquadex FlexFlow™ System

FDA's Statement of the Indication For Use for Device:

The Aquadex FlexFlow™ System is indicated for:

- Temporary (up to 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and
- Extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

All treatments must be administered by a health care provider, under physician prescription, both of whom having received training in extracorporeal therapies.